Latest news

• 24 April 2018

  Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced

  ▪ Lorenzo Pradella of GreenBone Ortho, srl has been...
• 24 April 2018

  1 Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy

  Lugano, Switzerland, and Tokyo, Japan, April 16, 2018 –...
• 24 April 2018

  Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/palonosetron) in the United States

  Lugano, Switzerland April 20, 2018 – Helsinn, a Swiss...